Loss of p300/CBP-associated factor aggravates cardiac remodeling via regulation of CAMKK2 acetylation

Yongwoon Lim1,2,3, Anna Jeong1,2, Duk-Hwa Kwon1,2

  • 1Department of Pharmacology, Chonnam National University Medical School, Hwasun, Republic of Korea.

Insights

The p300/CBP-associated factor (PCAF) regulates cardiac remodeling by acetylating CAMKK2, influencing AMPK signaling. Loss of PCAF worsens cardiac hypertrophy and dysfunction under stress, indicating PCAF as a therapeutic target.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Epigenetics

Background:

  • Pathological cardiac remodeling contributes to heart failure.
  • The role of epigenetic modifiers like PCAF in cardiac stress response is not fully understood.
  • Understanding molecular pathways is crucial for developing new therapies.

Purpose of the Study:

  • To elucidate the role of p300/CBP-associated factor (PCAF) in pathological cardiac remodeling.
  • To investigate how PCAF influences CAMKK2-AMPK signaling in the heart.
  • To evaluate PCAF as a potential therapeutic target for cardiac dysfunction.

Main Methods:

  • Generated global and cardiomyocyte-specific PCAF-knockout mouse models using CRISPR-Cas9.
  • Induced cardiac remodeling via isoproterenol infusion and transverse aortic constriction (TAC).
  • Performed histological analysis, echocardiography, and transcriptomic analysis.

Main Results:

  • PCAF deficiency aggravated cardiac enlargement and eccentric hypertrophy in response to stress.
  • PCAF directly acetylates CAMKK2, activating the CAMKK2-AMPKα signaling pathway.
  • Pharmacological activation of PCAF attenuated TAC-induced cardiac remodeling.

Conclusions:

  • PCAF is a key regulator of pathological cardiac remodeling via the CAMKK2-AMPK signaling axis.
  • Loss of PCAF exacerbates stress-induced cardiac hypertrophy and dysfunction.
  • Targeting PCAF may offer a novel therapeutic strategy for heart disease.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
789
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
4.8K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
930
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K